{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T07:45:21Z","timestamp":1792395921458,"version":"4.4.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13046-017-0667-1","type":"journal-article","created":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T13:12:26Z","timestamp":1517922746000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":198,"title":["Fate of Antibody-Drug Conjugates in Cancer Cells"],"prefix":"10.1186","volume":"37","author":[{"given":"C\u00e9cile","family":"Chalouni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Doll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,6]]},"reference":[{"issue":"2","key":"667_CR1","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.abb.2012.02.011","volume":"526","author":"J Golay","year":"2012","unstructured":"Golay J, Introna M. Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays. Arch Biochem Biophys. 2012;526(2):146\u201353.","journal-title":"Arch Biochem Biophys"},{"issue":"6151","key":"667_CR2","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1126\/science.1241145","volume":"341","author":"MX Sliwkowski","year":"2013","unstructured":"Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science. 2013;341(6151):1192\u20138.","journal-title":"Science"},{"issue":"1","key":"667_CR3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/cbdd.12085","volume":"81","author":"JA Flygare","year":"2013","unstructured":"Flygare JA, Pillow TH, Aristoff P. Antibody-drug conjugates for the treatment of cancer. Chem Biol Drug Des. 2013;81(1):113\u201321.","journal-title":"Chem Biol Drug Des"},{"issue":"2","key":"667_CR4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/nrd1957","volume":"5","author":"D Schrama","year":"2006","unstructured":"Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov. 2006;5(2):147\u201359.","journal-title":"Nat Rev Drug Discov"},{"issue":"20","key":"667_CR5","doi-asserted-by":"publisher","first-page":"6389","DOI":"10.1158\/1078-0432.CCR-11-1417","volume":"17","author":"BA Teicher","year":"2011","unstructured":"Teicher BA, Chari RV. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res. 2011;17(20):6389\u201397.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"667_CR6","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1158\/1535-7163.MCT-11-0727","volume":"11","author":"HK Erickson","year":"2012","unstructured":"Erickson HK, et al. The effect of different linkers on target cell catabolism and pharmacokinetics\/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther. 2012;11(5):1133\u201342.","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"667_CR7","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrd3270","volume":"9","author":"B Hughes","year":"2010","unstructured":"Hughes B. Antibody-drug conjugates for cancer: poised to deliver? Nat Rev Drug Discov. 2010;9(9):665\u20137.","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"667_CR8","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/nbt832","volume":"21","author":"SO Doronina","year":"2003","unstructured":"Doronina SO, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21(7):778\u201384.","journal-title":"Nat Biotechnol"},{"issue":"23","key":"667_CR9","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1016\/j.bmcl.2014.10.021","volume":"24","author":"H Bouchard","year":"2014","unstructured":"Bouchard H, Viskov C, Garcia-Echeverria C. Antibody-drug conjugates-a new wave of cancer drugs. Bioorg Med Chem Lett. 2014;24(23):5357\u201363.","journal-title":"Bioorg Med Chem Lett"},{"issue":"10","key":"667_CR10","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1158\/1535-7163.MCT-10-0645","volume":"9","author":"E Oroudjev","year":"2010","unstructured":"Oroudjev E, et al. Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol Cancer Ther. 2010;9(10):2700\u201313.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"667_CR11","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1021\/bc400217g","volume":"24","author":"SC Jeffrey","year":"2013","unstructured":"Jeffrey SC, et al. A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. Bioconjug Chem. 2013;24(7):1256\u201363.","journal-title":"Bioconjug Chem"},{"issue":"57","key":"667_CR12","doi-asserted-by":"publisher","first-page":"9107","DOI":"10.1038\/sj.onc.1207196","volume":"22","author":"A Prokop","year":"2003","unstructured":"Prokop A, et al. Induction of apoptosis by enediyne antibiotic calicheamicin thetaII proceeds through a caspase-mediated mitochondrial amplification loop in an entirely Bax-dependent manner. Oncogene. 2003;22(57):9107\u201320.","journal-title":"Oncogene"},{"issue":"1","key":"667_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/1074-5521(94)90041-8","volume":"1","author":"KC Nicolaou","year":"1994","unstructured":"Nicolaou KC, et al. Synthetic calicheamicin mimics with novel initiation mechanisms: DNA cleavage, cytotoxicity, and apoptosis. Chem Biol. 1994;1(1):57\u201366.","journal-title":"Chem Biol"},{"issue":"5","key":"667_CR14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.clbc.2011.03.018","volume":"11","author":"HA Burris 3rd","year":"2011","unstructured":"Burris HA 3rd, et al. Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer. Clin Breast Cancer. 2011;11(5):275\u201382.","journal-title":"Clin Breast Cancer"},{"issue":"5","key":"667_CR15","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/bjh.13992","volume":"173","author":"B Coiffier","year":"2016","unstructured":"Coiffier B, et al. A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. Br J Haematol. 2016;173(5):722\u201330.","journal-title":"Br J Haematol"},{"issue":"24","key":"667_CR16","doi-asserted-by":"publisher","first-page":"4838","DOI":"10.1182\/blood-2013-03-490482","volume":"121","author":"JM Rowe","year":"2013","unstructured":"Rowe JM, Lowenberg B. Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. Blood. 2013;121(24):4838\u201341.","journal-title":"Blood"},{"issue":"8","key":"667_CR17","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1182\/blood-2013-03-491506","volume":"122","author":"MS Kung Sutherland","year":"2013","unstructured":"Kung Sutherland MS, et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013;122(8):1455\u201363.","journal-title":"Blood"},{"issue":"26","key":"667_CR18","doi-asserted-by":"publisher","first-page":"22496","DOI":"10.18632\/oncotarget.4318","volume":"6","author":"DM Goldenberg","year":"2015","unstructured":"Goldenberg DM, et al. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015;6(26):22496\u2013512.","journal-title":"Oncotarget"},{"issue":"2","key":"667_CR19","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.2108","volume":"30","author":"BQ Shen","year":"2012","unstructured":"Shen BQ, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol. 2012;30(2):184\u20139.","journal-title":"Nat Biotechnol"},{"issue":"5","key":"667_CR20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315\u201337.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"667_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4161\/mabs.22854","volume":"5","author":"M Ritchie","year":"2013","unstructured":"Ritchie M, Tchistiakova L, Scott N. Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. MAbs. 2013;5(1):13\u201321.","journal-title":"MAbs"},{"key":"667_CR22","doi-asserted-by":"crossref","unstructured":"Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015;35(4)","DOI":"10.1042\/BSR20150089"},{"key":"667_CR23","unstructured":"Parslow AC, et al. Antibody-drug conjugates for cancer therapy. Biomedicine. 2016;4(3):1-17."},{"issue":"6","key":"667_CR24","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1158\/0008-5472.CAN-05-3973","volume":"66","author":"YV Kovtun","year":"2006","unstructured":"Kovtun YV, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 2006;66(6):3214\u201321.","journal-title":"Cancer Res"},{"issue":"2","key":"667_CR25","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.canlet.2007.04.010","volume":"255","author":"YV Kovtun","year":"2007","unstructured":"Kovtun YV, Goldmacher VS. Cell killing by antibody-drug conjugates. Cancer Lett. 2007;255(2):232\u201340.","journal-title":"Cancer Lett"},{"issue":"1","key":"667_CR26","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4155\/ppa.12.4","volume":"1","author":"B Sammet","year":"2012","unstructured":"Sammet B, Steinkuhler C, Sewald N. Antibody-drug conjugates in tumor therapy. Pharm Pat Anal. 2012;1(1):65\u201373.","journal-title":"Pharm Pat Anal"},{"key":"667_CR27","doi-asserted-by":"crossref","unstructured":"Sigismund, S., et al., Endocytosis and signaling: cell logistics shape the eukaryotic cell plan. Physiol Rev, 2012. 92(1): p. 273-366.","DOI":"10.1152\/physrev.00005.2011"},{"key":"667_CR28","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1146\/annurev.biochem.78.081307.110540","volume":"78","author":"GJ Doherty","year":"2009","unstructured":"Doherty GJ, McMahon HT. Mechanisms of endocytosis. Annu Rev Biochem. 2009;78:857\u2013902.","journal-title":"Annu Rev Biochem"},{"issue":"7280","key":"667_CR29","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nature08910","volume":"463","author":"G Scita","year":"2010","unstructured":"Scita G, Di Fiore PP. The endocytic matrix. Nature. 2010;463(7280):464\u201373.","journal-title":"Nature"},{"issue":"6927","key":"667_CR30","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nature01451","volume":"422","author":"SD Conner","year":"2003","unstructured":"Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature. 2003;422(6927):37\u201344.","journal-title":"Nature"},{"issue":"2","key":"667_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/nrm3266","volume":"13","author":"SM Ferguson","year":"2012","unstructured":"Ferguson SM, De Camilli P. Dynamin, a membrane-remodelling GTPase. Nat Rev Mol Cell Biol. 2012;13(2):75\u201388.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"8","key":"667_CR32","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrm2728","volume":"10","author":"H Stenmark","year":"2009","unstructured":"Stenmark H. Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol. 2009;10(8):513\u201325.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"667_CR33","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.ceb.2006.06.002","volume":"18","author":"MR Russell","year":"2006","unstructured":"Russell MR, Nickerson DP, Odorizzi G. Molecular mechanisms of late endosome morphology, identity and sorting. Curr Opin Cell Biol. 2006;18(4):422\u20138.","journal-title":"Curr Opin Cell Biol"},{"issue":"22","key":"667_CR34","doi-asserted-by":"publisher","first-page":"5037","DOI":"10.1158\/1078-0432.CCR-15-0490","volume":"21","author":"E White","year":"2015","unstructured":"White E, Mehnert JM, Chan CS. Autophagy, metabolism, and cancer. Clin Cancer Res. 2015;21(22):5037\u201346.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"667_CR35","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nrm2217","volume":"8","author":"JP Luzio","year":"2007","unstructured":"Luzio JP, Pryor PR, Bright NA. Lysosomes: fusion and function. Nat Rev Mol Cell Biol. 2007;8(8):622\u201332.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"8","key":"667_CR36","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1158\/0008-5472.CAN-16-3403","volume":"77","author":"L Lanzetti","year":"2017","unstructured":"Lanzetti L, Di Fiore PP. Behind the scenes: Endo\/Exocytosis in the Acquisition of Metastatic Traits. Cancer Res. 2017;77(8):1813\u20137.","journal-title":"Cancer Res"},{"issue":"12","key":"667_CR37","doi-asserted-by":"publisher","first-page":"a016949","DOI":"10.1101\/cshperspect.a016949","volume":"5","author":"I Mellman","year":"2013","unstructured":"Mellman I, Yarden Y. Endocytosis and cancer. Cold Spring Harb Perspect Biol. 2013;5(12):a016949.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"11","key":"667_CR38","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/nrc2521","volume":"8","author":"Y Mosesson","year":"2008","unstructured":"Mosesson Y, Mills GB, Yarden Y. Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer. 2008;8(11):835\u201350.","journal-title":"Nat Rev Cancer"},{"key":"667_CR39","doi-asserted-by":"crossref","unstructured":"Davidson, S.M. and M.G. Vander Heiden, Critical functions of the Lysosome in cancer biology. Annu Rev Pharmacol Toxicol, 2017. 57: p. 481-507.","DOI":"10.1146\/annurev-pharmtox-010715-103101"},{"issue":"23","key":"667_CR40","doi-asserted-by":"publisher","first-page":"7842","DOI":"10.1158\/1078-0432.CCR-04-1028","volume":"10","author":"CL Law","year":"2004","unstructured":"Law CL, et al. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates. Clin Cancer Res. 2004;10(23):7842\u201351.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"667_CR41","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1365-2141.2007.06883.x","volume":"140","author":"GS Ingle","year":"2008","unstructured":"Ingle GS, et al. High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate. Br J Haematol. 2008;140(1):46\u201358.","journal-title":"Br J Haematol"},{"issue":"18","key":"667_CR42","doi-asserted-by":"publisher","first-page":"4352","DOI":"10.1182\/blood-2008-09-179143","volume":"113","author":"HP Gerber","year":"2009","unstructured":"Gerber HP, et al. Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas. Blood. 2009;113(18):4352\u201361.","journal-title":"Blood"},{"issue":"6","key":"667_CR43","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood.V81.6.1549.1549","volume":"81","author":"S Pulczynski","year":"1993","unstructured":"Pulczynski S, Boesen AM, Jensen OM. Antibody-induced modulation and intracellular transport of CD10 and CD19 antigens in human B-cell lines: an immunofluorescence and immunoelectron microscopy study. Blood. 1993;81(6):1549\u201357.","journal-title":"Blood"},{"issue":"1","key":"667_CR44","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1021\/ar700108g","volume":"41","author":"RV Chari","year":"2008","unstructured":"Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2008;41(1):98\u2013107.","journal-title":"Acc Chem Res"},{"issue":"1","key":"667_CR45","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1517\/13543784.2011.542147","volume":"20","author":"SM Ansell","year":"2011","unstructured":"Ansell SM. Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells. Expert Opin Investig Drugs. 2011;20(1):99\u2013105.","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"667_CR46","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/172460089901400303","volume":"14","author":"A Younes","year":"1999","unstructured":"Younes A, Carbone A. CD30\/CD30 ligand and CD40\/CD40 ligand in malignant lymphoid disorders. Int J Biol Markers. 1999;14(3):135\u201343.","journal-title":"Int J Biol Markers"},{"issue":"15","key":"667_CR47","doi-asserted-by":"publisher","first-page":"10540","DOI":"10.1074\/jbc.M510026200","volume":"281","author":"MS Sutherland","year":"2006","unstructured":"Sutherland MS, et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem. 2006;281(15):10540\u20137.","journal-title":"J Biol Chem"},{"issue":"3","key":"667_CR48","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1158\/1078-0432.CCR-09-2069","volume":"16","author":"NM Okeley","year":"2010","unstructured":"Okeley NM, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res. 2010;16(3):888\u201397.","journal-title":"Clin Cancer Res"},{"key":"667_CR49","doi-asserted-by":"crossref","unstructured":"Kuppers R. Molecular biology of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2009:491\u20136.","DOI":"10.1182\/asheducation-2009.1.491"},{"key":"667_CR50","doi-asserted-by":"crossref","unstructured":"Masuda S, et al. CD30-targeting immunoconjugates and bystander effects. Nat Rev Clin Oncol. 2015;12(4)","DOI":"10.1038\/nrclinonc.2014.159-c1"},{"issue":"5","key":"667_CR51","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/clpt.2014.24","volume":"95","author":"J Wang","year":"2014","unstructured":"Wang J, et al. Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer. Clin Pharmacol Ther. 2014;95(5):558\u201364.","journal-title":"Clin Pharmacol Ther"},{"issue":"19","key":"667_CR52","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783\u201391.","journal-title":"N Engl J Med"},{"issue":"4905","key":"667_CR53","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon DJ, et al. Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707\u201312.","journal-title":"Science"},{"key":"667_CR54","doi-asserted-by":"crossref","unstructured":"Yarden RI, Wilson MA, Chrysogelos SA. Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth. J Cell Biochem Suppl. 2001;(Suppl 36):232\u201346.","DOI":"10.1002\/jcb.1142"},{"issue":"22","key":"667_CR55","doi-asserted-by":"publisher","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","volume":"68","author":"GD Lewis Phillips","year":"2008","unstructured":"Lewis Phillips GD, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68(22):9280\u201390.","journal-title":"Cancer Res"},{"issue":"12","key":"667_CR56","doi-asserted-by":"publisher","first-page":"5268","DOI":"10.1091\/mbc.E04-07-0591","volume":"15","author":"CD Austin","year":"2004","unstructured":"Austin CD, et al. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell. 2004;15(12):5268\u201382.","journal-title":"Mol Biol Cell"},{"key":"667_CR57","doi-asserted-by":"publisher","first-page":"e1149","DOI":"10.1038\/cddis.2014.115","volume":"5","author":"J Diessner","year":"2014","unstructured":"Diessner J, et al. Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1). Cell Death Dis. 2014;5:e1149.","journal-title":"Cell Death Dis"},{"issue":"1","key":"667_CR58","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s12015-007-0004-8","volume":"3","author":"O Dreesen","year":"2007","unstructured":"Dreesen O, Brivanlou AH. Signaling pathways in cancer and embryonic stem cells. Stem Cell Rev. 2007;3(1):7\u201317.","journal-title":"Stem Cell Rev"},{"issue":"3","key":"667_CR59","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1124\/jpet.103.060533","volume":"308","author":"H Xie","year":"2004","unstructured":"Xie H, et al. Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice. J Pharmacol Exp Ther. 2004;308(3):1073\u201382.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"667_CR60","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/bcr3621","volume":"16","author":"M Barok","year":"2014","unstructured":"Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 2014;16(2):209.","journal-title":"Breast Cancer Res"},{"issue":"2","key":"667_CR61","doi-asserted-by":"publisher","first-page":"R46","DOI":"10.1186\/bcr2868","volume":"13","author":"M Barok","year":"2011","unstructured":"Barok M, et al. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res. 2011;13(2):R46.","journal-title":"Breast Cancer Res"},{"issue":"13","key":"667_CR62","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1038\/sj.onc.1202526","volume":"18","author":"M Pegram","year":"1999","unstructured":"Pegram M, et al. Inhibitory effects of combinations of HER-2\/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 1999;18(13):2241\u201351.","journal-title":"Oncogene"},{"issue":"2","key":"667_CR63","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1158\/1078-0432.CCR-13-0358","volume":"20","author":"GD Phillips","year":"2014","unstructured":"Phillips GD, et al. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. Clin Cancer Res. 2014;20(2):456\u201368.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"667_CR64","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ccell.2015.12.008","volume":"29","author":"JY Li","year":"2016","unstructured":"Li JY, et al. A Biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer Cell. 2016;29(1):117\u201329.","journal-title":"Cancer Cell"},{"issue":"6","key":"667_CR65","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1158\/0008-5472.CAN-09-3546","volume":"70","author":"YV Kovtun","year":"2010","unstructured":"Kovtun YV, et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res. 2010;70(6):2528\u201337.","journal-title":"Cancer Res"},{"issue":"30","key":"667_CR66","doi-asserted-by":"publisher","first-page":"13252","DOI":"10.1073\/pnas.0913476107","volume":"107","author":"JB Spangler","year":"2010","unstructured":"Spangler JB, et al. Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc Natl Acad Sci U S A. 2010;107(30):13252\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"667_CR67","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1073\/pnas.0409610102","volume":"102","author":"LM Friedman","year":"2005","unstructured":"Friedman LM, et al. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci U S A. 2005;102(6):1915\u201320.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"26","key":"667_CR68","doi-asserted-by":"publisher","first-page":"6198","DOI":"10.1182\/blood-2011-11-325050","volume":"119","author":"RB Walter","year":"2012","unstructured":"Walter RB, et al. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood. 2012;119(26):6198\u2013208.","journal-title":"Blood"},{"issue":"9","key":"667_CR69","first-page":"3323","volume":"89","author":"CP Leith","year":"1997","unstructured":"Leith CP, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study Blood. 1997;89(9):3323\u20139.","journal-title":"A Southwest Oncology Group study Blood"},{"issue":"7578","key":"667_CR70","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nature16057","volume":"527","author":"SM Lehar","year":"2015","unstructured":"Lehar SM, et al. Novel antibody-antibiotic conjugate eliminates intracellular S. Aureus. Nature. 2015;527(7578):323\u20138.","journal-title":"Nature"},{"issue":"2","key":"667_CR71","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1182\/blood-2007-01-066704","volume":"110","author":"AG Polson","year":"2007","unstructured":"Polson AG, et al. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood. 2007;110(2):616\u201323.","journal-title":"Blood"},{"issue":"2","key":"667_CR72","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.bbamcr.2015.12.002","volume":"1863","author":"R Ojha","year":"2016","unstructured":"Ojha R, Jha V, Singh SK. Gemcitabine and mitomycin induced autophagy regulates cancer stem cell pool in urothelial carcinoma cells. Biochim Biophys Acta. 2016;1863(2):347\u201359.","journal-title":"Biochim Biophys Acta"},{"issue":"1\u20133","key":"667_CR73","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1387\/ijdb.150082iv","volume":"59","author":"I Vitale","year":"2015","unstructured":"Vitale I, et al. Role of autophagy in the maintenance and function of cancer stem cells. Int J Dev Biol. 2015;59(1\u20133):95\u2013108.","journal-title":"Int J Dev Biol"},{"key":"667_CR74","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.canlet.2017.02.012","volume":"393","author":"Y Lei","year":"2017","unstructured":"Lei Y, et al. Targeting autophagy in cancer stem cells as an anticancer therapy. Cancer Lett. 2017;393:33\u20139.","journal-title":"Cancer Lett"},{"issue":"302","key":"667_CR75","doi-asserted-by":"publisher","first-page":"302ra136","DOI":"10.1126\/scitranslmed.aac9459","volume":"7","author":"LR Saunders","year":"2015","unstructured":"Saunders LR, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med. 2015;7(302):302ra136.","journal-title":"Sci Transl Med"},{"issue":"42","key":"667_CR76","doi-asserted-by":"publisher","first-page":"29218","DOI":"10.1074\/jbc.M109.014993","volume":"284","author":"M Mairhofer","year":"2009","unstructured":"Mairhofer M, et al. Stomatin-like protein-1 interacts with stomatin and is targeted to late endosomes. J Biol Chem. 2009;284(42):29218\u201329.","journal-title":"J Biol Chem"},{"issue":"24","key":"667_CR77","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.1158\/0008-5472.CAN-15-1610","volume":"75","author":"KJ Hamblett","year":"2015","unstructured":"Hamblett KJ, et al. SLC46A3 is required to transport Catabolites of noncleavable antibody Maytansine conjugates from the Lysosome to the cytoplasm. Cancer Res. 2015;75(24):5329\u201340.","journal-title":"Cancer Res"},{"key":"667_CR78","doi-asserted-by":"crossref","unstructured":"Wang H, et al. Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells. Cancer Sci. 2017;108(7):1458\u201468.","DOI":"10.1111\/cas.13253"},{"issue":"4","key":"667_CR79","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1158\/1535-7163.MCT-14-0862","volume":"14","author":"F Loganzo","year":"2015","unstructured":"Loganzo F, et al. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments. Mol Cancer Ther. 2015;14(4):952\u201363.","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"667_CR80","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-16-0408","volume":"15","author":"F Loganzo","year":"2016","unstructured":"Loganzo F, Sung M, Gerber HP. Mechanisms of resistance to antibody-drug conjugates. Mol Cancer Ther. 2016;15(12):2825\u201334.","journal-title":"Mol Cancer Ther"},{"issue":"14","key":"667_CR81","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1158\/1078-0432.CCR-14-2035","volume":"21","author":"SF Yu","year":"2015","unstructured":"Yu SF, et al. A novel anti-CD22 Anthracycline-based antibody-drug conjugate (ADC) that overcomes resistance to Auristatin-based ADCs. Clin Cancer Res. 2015;21(14):3298\u2013306.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"667_CR82","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1124\/mol.114.091850","volume":"85","author":"A Thorburn","year":"2014","unstructured":"Thorburn A, Thamm DH, Gustafson DL. Autophagy and cancer therapy. Mol Pharmacol. 2014;85(6):830\u20138.","journal-title":"Mol Pharmacol"},{"issue":"1","key":"667_CR83","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/nyas.12953","volume":"1371","author":"S Piao","year":"2016","unstructured":"Piao S, Amaravadi RK. Targeting the lysosome in cancer. Ann N Y Acad Sci. 2016;1371(1):45\u201354.","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"667_CR84","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1158\/1078-0432.CCR-10-2634","volume":"17","author":"RK Amaravadi","year":"2011","unstructured":"Amaravadi RK, et al. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res. 2011;17(4):654\u201366.","journal-title":"Clin Cancer Res"},{"issue":"1\u20132","key":"667_CR85","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.cellimm.2005.08.024","volume":"236","author":"EJ Parkinson-Lawrence","year":"2005","unstructured":"Parkinson-Lawrence EJ, et al. Immunochemical analysis of CD107a (LAMP-1). Cell Immunol. 2005;236(1\u20132):161\u20136.","journal-title":"Cell Immunol"},{"issue":"9","key":"667_CR86","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1007\/s00432-015-1917-2","volume":"141","author":"AK Agarwal","year":"2015","unstructured":"Agarwal AK, et al. Role of tumor cell surface lysosome-associated membrane protein-1 (LAMP1) and its associated carbohydrates in lung metastasis. J Cancer Res Clin Oncol. 2015;141(9):1563\u201374.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"667_CR87","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0002-9440(10)61716-6","volume":"159","author":"K Furuta","year":"2001","unstructured":"Furuta K, et al. Expression of lysosome-associated membrane proteins in human colorectal neoplasms and inflammatory diseases. Am J Pathol. 2001;159(2):449\u201355.","journal-title":"Am J Pathol"},{"issue":"3","key":"667_CR88","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.3892\/or.2014.2981","volume":"31","author":"KT Chan","year":"2014","unstructured":"Chan KT, et al. Overexpression of transferrin receptor CD71 and its tumorigenic properties in esophageal squamous cell carcinoma. Oncol Rep. 2014;31(3):1296\u2013304.","journal-title":"Oncol Rep"},{"issue":"16","key":"667_CR89","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1038\/onc.2012.292","volume":"32","author":"T Kallunki","year":"2013","unstructured":"Kallunki T, Olsen OD, Jaattela M. Cancer-associated lysosomal changes: friends or foes? Oncogene. 2013;32(16):1995\u20132004.","journal-title":"Oncogene"},{"issue":"9","key":"667_CR90","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1093\/annonc\/mdv209","volume":"26","author":"L Apetoh","year":"2015","unstructured":"Apetoh L, et al. Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? Ann Oncol. 2015;26(9):1813\u201323.","journal-title":"Ann Oncol"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-017-0667-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:29:11Z","timestamp":1719793751000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-017-0667-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,6]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["667"],"URL":"https:\/\/doi.org\/10.1186\/s13046-017-0667-1","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,6]]},"assertion":[{"value":"15 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"20"}}